Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-02-05 00:00:00 ET · period of report 2026-02-04 · accession 0001902368-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-05 | 2026-02-04 | TVTX | Inrig Jula | Chief MEDICAL Off | S - Sale | $32.21 | -1,779 | 105.9K | -2% | -$57.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-04 | S | D | 232 | $32.85 | 105,706 | D | — | — | (F3) The weighted average sale price for the transaction reported was $32.85, and the range of prices were between $32.80 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 2 | Common | Common Stock | 2026-02-04 | S | D | 1,547 | $32.11 | 105,938 | D | — | — | (F2) The weighted average sale price for the transaction reported was $32.11, and the range of prices were between $31.65 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |